GSK Secures FDA Approval for Hepatitis B Drug Hibsago
The new antisense oligonucleotide offers a treatment option for patients managing chronic hepatitis B virus infections.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Is now a good time to pursue new, high-monitoring specialty drug therapies for chronic conditions?
GSK has received FDA approval for Hibsago, a specialized treatment for patients with chronic hepatitis B who have undergone at least six months of Nrtl therapy. The company plans to begin rolling out the drug in the United States within ten days of October 28, 2026.
Why it matters
Hibsago addresses a significant unmet need for patients with chronic hepatitis B, with GSK targeting a concentrated patient population across the U.S. Analysts project the drug could reach peak sales of 2.2 billion pounds.
GSK reported 8.9 billion pounds in third-quarter sales, while specialty medicine revenue grew 15% to reach 3.9 billion pounds. The company maintains an ambitious long-term goal to exceed 40 billion pounds in total sales by 2031.
The players
GSK
This British multinational pharmaceutical and biotechnology company focuses on the development and manufacturing of medicines and vaccines.
FDA
The U.S. Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
Jefferies
This global financial services company provides investment banking and capital markets services and issued the sales projections for the drug.
The details
Patients qualify for Hibsago if they have suppressed virus DNA and surface antigen levels no greater than 3000 IU/ml. The FDA-approved label includes a black box warning alerting physicians to monitor for potential hepatic flares and thrombocytopenia.
Timeline
October 2026: GSK received FDA approval for the drug Hibsago.
November 7, 2026: The drug is estimated to become available in the U.S. market.
2027: GSK is scheduled to release data on a new three-times-a-year Cabenuva formulation.
2031: The company has set a goal to reach 40 billion pounds in annual sales.
Market Landscape
This launch reinforces GSK's pivot toward high-growth specialty medicines as the company balances restructuring charges with a 15% revenue growth in its specialty segment. The move positions GSK to capture significant share in the hepatitis B market across major regions including China and Japan.
Patients who meet the strict clinical eligibility criteria may soon gain access to this new treatment through their healthcare providers. Prospective users should discuss the specific black box warnings regarding liver health with their doctors prior to starting treatment.
The takeaway
Patients managing chronic hepatitis B should monitor their surface antigen levels closely to determine if they meet the specific eligibility criteria for new therapies. Consult with a specialized medical provider to understand the safety protocols required when beginning antisense oligonucleotide treatments.
What happens next
GSK plans to launch the drug in the United States by November 7, 2026, and is slated to report data for its new Cabenuva formulation in 2027.
Further reading
For additional context on industry trends, visit the Healthcare section.
Source note: This article includes information reported by FiercePharma.
Live Poll
Is now a good time to pursue new, high-monitoring specialty drug therapies for chronic conditions?
